| Next 10 |
SAVA News and Press, Cassava Sciences Inc.
-
Cassava Sciences shares are +3,300% in the past year, but the upside could continue until the $4.5bn market cap biotech achieves a >$50bn valuation. Cassava is developing an Alzheimer's therapy in Simufilam that early data suggests may be able to reverse cognitive decline, rather t...
-
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
-
There are no Alzheimer's modifying therapies on market for one of the world's greatest challenges - aducanumab does not look like the answer. Cassava's simufilam has a unique approach and highly differentiated data. Impending nine-month data could be simufilam's coming out party. ...
-
Shares of Cassava Sciences Inc. (NASDAQ:SAVA) traded today at $132.88, eclipsing its 52-week high. This new high was reached on below average trading volume as 1 million shares traded hands, while the average 30-day volume is approximately 3.5 million shares. Cassava Sciences Inc. (NASDA...
-
Cassava Sciences (SAVA) perks up 4% premarket after announcing positive clinical data with SavaDx, an investigational diagnostic/biomarker to detect Alzheimer’s disease ((AD)) with a simple blood test.In this Phase 2b trial, simufilam significantly reduced plasma levels of al...
-
SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam Treatment Simufilam 100 mg and 50 mg Reduced Plasma Levels of Altered Filamin A in Alzheimer’s Patients 48% (p=0.003) and 4...
-
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
-
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Tech heavyweights will be in the spotlight next week with Apple (NASDAQ:AAPL), Microsoft (NASDAQ:MSFT), Alphabet (NASDAQ...
-
Artystarty/iStock via Getty Images The healthcare stocks in the S&P 500 finished ~2.2% higher this week to outperform the ~2.0% gain recorded by the broader index over the past five-day period. While the stocks weighed down by their alleged involvement in the U.S. opioid crisis ...
-
knowlesgallery/iStock via Getty Images The Alzheimer's Association International Conference begins Monday and runs through July 30 both in person in Denver and online. As always, there are several eagerly awaited presentations from companies working on Alzheimer's therapies that could lead to...
Stock Information
Cassava Sciences Inc. Company Name:
SAVA Stock Symbol:
NYSE Market:
MENU
SAVA
SAVA Quote
SAVA Short
SAVA News
SAVA Articles
Get SAVA Alerts
News, Short Squeeze, Breakout and More Instantly...
-
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
-
Shares of Cassava Sciences Inc. (NASDAQ:SAVA) traded today at $132.88, eclipsing its 52-week high. This new high was reached on below average trading volume as 1 million shares traded hands, while the average 30-day volume is approximately 3.5 million shares. Cassava Sciences Inc. (NASDA...
-
SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam Treatment Simufilam 100 mg and 50 mg Reduced Plasma Levels of Altered Filamin A in Alzheimer’s Patients 48% (p=0.003) and 4...